<DOC>
	<DOCNO>NCT01419028</DOCNO>
	<brief_summary>This study aim characterize natural history patient severe perinatal infantile onset HPP .</brief_summary>
	<brief_title>A Retrospective Study Natural History Patients With Severe Perinatal Infantile Hypophosphatasia ( HPP )</brief_title>
	<detailed_description>Hypophosphatasia ( HPP ) life-threatening , genetic , ultra-rare metabolic disease characterize defective bone mineralization impair phosphate calcium regulation lead progressive damage multiple vital organ , include destruction deformity bone , profound muscle weakness , seizure , impair renal function , respiratory failure . There approve disease-modifying treatment patient disease . There also limit data available natural course disease time , particularly patient juvenile-onset form .</detailed_description>
	<mesh_term>Hypophosphatasia</mesh_term>
	<criteria>Parent ( ) legal guardian ( ) must provide write informed consent prior data abstraction , unless follow apply : The patient decease ; AND The responsible IRB/IEC/REB require inform consent per review document local policy collect retrospective data patient decease ; AND Written confirmation receive responsible IRB/IEC/REB confirming abstract data analyzed use support regulatory filing Sponsor Patient must document diagnosis HPP indicate 1 following : Documented ALPL gene mutation ( ) Serum alkaline phosphatase ( ALP ) ageadjusted normal range either plasma pyridoxal 5'phosphate ( PLP ) urinary phosphoethanolamine ( PEA ) upper limit normal Serum ALP ageadjusted normal range HPPrelated radiographic abnormality Xray Patient must onset sign HPP prior 6 month age documentation 1 follow characteristic perinatal infantile HPP : Respiratory compromise ( include respiratory failure ) require institution respiratory support measure ( ) , require medication ( ) management symptom ( ) , and/or associate respiratory complication ( e.g. , pneumonia ( ) , respiratory tract infection ( ) ) Pyridoxine ( vitamin B6 ) responsive seizure Rachitic chest deformity Patients exclude study participation 1 follow exclusion criterion : Patient receive treatment asfotase alfa time prior data abstraction Patient clinically significant disease Both living decease patient consider study participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hypophosphatasia</keyword>
	<keyword>HPP</keyword>
	<keyword>Bone disease</keyword>
	<keyword>Soft bone</keyword>
	<keyword>Low alkaline phosphatase</keyword>
	<keyword>Genetic metabolic disorder</keyword>
	<keyword>Alkaline phosphatase</keyword>
	<keyword>Tissue non-specific alkaline phosphatase</keyword>
	<keyword>Rickets</keyword>
	<keyword>Osteomalacia</keyword>
</DOC>